首页> 外文期刊>Journal of the Iranian Chemical Society >Interaction of the synthesized anticancer compound of the methyl-glycine 1,10-phenanthroline platinum nitrate with human serum albumin and human hemoglobin proteins by spectroscopy methods and molecular docking
【24h】

Interaction of the synthesized anticancer compound of the methyl-glycine 1,10-phenanthroline platinum nitrate with human serum albumin and human hemoglobin proteins by spectroscopy methods and molecular docking

机译:甲基 - 甘氨酸1,10-菲林铂的合成抗癌化合物与人血清白蛋白和人血红蛋白蛋白的光谱法和分子对接的相互作用

获取原文
获取原文并翻译 | 示例
           

摘要

In the present study, the interaction of the novel synthesized platinum complex named methyl-glycine 1,10-phenanthroline platinum nitrate product with two most crucial blood carrier proteins of hemoglobin (Hb) and human serum albumin (HSA) has been investigated. Notably, structural alternation ability of the above anticancer compound was assessed at various temperatures through multispectroscopic techniques such as far-UV circular dichroism (CD) and fluorescence with the participation of the molecular docking targeting Hb and HSA in the systems of the medicine delivery. Fluctuations in the inherent fluorescence intensities of the proteins in consequence of the Pt(II) complex binding represented statics of the quenching system. It should be mentioned that thermodynamic and binding parameters have been calculated through the analysis of the outcomes of the quenching and outcomes of van't Hoff equation for the two proteins. Theoretical and experimental findings pointed out that the leading force for the Pt(II) complex interaction was electrostatic for HSA and hydrophobic interactions for Hb. Moreover, fluorescence experiments discovered that one binding site would be available because of the Pt(II) complex binding in the two proteins accompanied by a negative Gibbs free energy value. Additionally, the far-UV CD outputs suggested that the Pt(II) complex would cause some variations in the regular secondary and tertiary structures of the HSA as the remarkable going down in the alpha helical contents of proteins structures at different temperatures equal to 25 degrees C and 37 degrees C; however, any noteworthy modifications have not been seen in the respective structures of Hb. However, the interaction between the newly made-up medicine (Pt(II) complex) and the two most crucial blood carrier proteins of the Hb and HSA made a notable shifting in the structures and conformations of the proteins via many fluctuations in the secondary and tertiary structures of the two proteins. Hence, such researches of designing the novel metal anticancer medicines may gather useful data for exploring the more suitable path in the face-off with severe disorders like various cancers through inventing and developing metal medical compounds that are more advantageous and have fewer consequences.
机译:在本研究中,研究了具有血红蛋白(HB)和人血清白蛋白(HSA)的两个最关键的血液载体蛋白硝酸铂产物的新型合成铂复合物的相互作用。值得注意的是,通过多光谱技术(如FAR-UV圆形二色性(CD)和荧光在药物递送系统中,通过多光谱循环技术(CD)和荧光来评估上述抗癌化合物的结构交替能力。蛋白质的固有荧光强度的波动,其Pt(II)复合物结合的代表淬火系统的静止静态。应该提到的是,通过分析两种蛋白质的Vace't Hoff方程的淬火和结果的结果来计算热力学和结合参数。理论和实验结果指出,Pt(ii)的主要电力为Hb的HSA和疏水相互作用是静电的。此外,荧光实验发现,由于两种蛋白质中的Pt(II)复合物结合,所以可以获得一个结合位点。另外,远UV CD输出表明PT(II)复合物将导致HSA的常规二级和三级结构的一些变化,因为在不同温度的蛋白质结构的α螺旋含量中的显着下降,等于25度C和37摄氏度;然而,在HB的各个结构中没有看到任何值得注意的修改。然而,新制备药物(Pt(ii)复合物之间的相互作用(Pt(ii)复合物)和Hb和Hsa的两个最关键的血液载体蛋白在蛋白质的结构和蛋白质的构象中产生了显着的移位,并且通过中等的许多波动两种蛋白质的三级结构。因此,设计新的金属抗癌药物的这种研究可以通过发明和开发更有利的金属医学化合物和产生更少的金属医学化合物,利用各种癌症的严重疾病来利用探索更合适的路径来探索更合适的路径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号